• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The economics of treating obesity.

作者信息

Hutton J

机构信息

Battelle MEDTAP Research Centre, London, England.

出版信息

Pharmacoeconomics. 1994;5(Suppl 1):66-72. doi: 10.2165/00019053-199400051-00014.

DOI:10.2165/00019053-199400051-00014
PMID:10147253
Abstract

Obesity has become a major contemporary public health concern. The excess burden of disease associated with obesity (e.g. cardiovascular disease, diabetes mellitus, gallbladder disease) results in considerable costs to society, while the indirect costs of obesity include decreased labour input and lower educational achievement. Obese individuals have decreased quality of life and life expectancy. Furthermore, society's stigmatisation of the obese results in decreased opportunities in education, housing and employment. Obesity may be treated by behavioural modification (dieting, exercise), or by interventionist means (pharmacotherapy, jaw-wiring, surgery). The method of weight reduction should be chosen to suit the individual patient; interventionist approaches may be required for patients with severe obesity. Studies to examine the cost and quality of life implications of the various treatment modalities are needed.

摘要

相似文献

1
The economics of treating obesity.
Pharmacoeconomics. 1994;5(Suppl 1):66-72. doi: 10.2165/00019053-199400051-00014.
2
Outcomes of pharmacological and surgical treatment for obesity.肥胖症的药物治疗和手术治疗结果。
Pharmacoeconomics. 1998 Sep;14(3):269-83. doi: 10.2165/00019053-199814030-00004.
3
Modeling the clinical and economic implications of obesity using microsimulation.使用微观模拟对肥胖的临床和经济影响进行建模。
J Med Econ. 2015;18(11):886-97. doi: 10.3111/13696998.2015.1058805. Epub 2015 Aug 13.
4
[Juvenile obesity and comorbidity type 2 diabetes mellitus (T2 DM) in Germany: development and cost-of-illness analysis].[德国青少年肥胖与2型糖尿病合并症:发展情况及疾病成本分析]
Gesundheitswesen. 2006 Oct;68(10):600-12. doi: 10.1055/s-2006-927181.
5
Health economics of weight management: evidence and cost.体重管理的健康经济学:证据与成本
Asia Pac J Clin Nutr. 2007;16 Suppl 1:329-38.
6
[Health risks and economic costs associated with obesity requiring a comprehensive weight reduction program].[与肥胖相关的健康风险和经济成本需要全面的减重计划]
Cas Lek Cesk. 1997 Jun 12;136(12):367-72.
7
Economic costs of obesity.肥胖的经济成本。
Am J Clin Nutr. 1992 Feb;55(2 Suppl):503S-507S. doi: 10.1093/ajcn/55.2.503s.
8
Economics and obesity: costing the problem or evaluating solutions?经济学与肥胖问题:计算问题成本还是评估解决方案?
Obes Res. 2004 Feb;12(2):173-9. doi: 10.1038/oby.2004.23.
9
The clinical and economic consequences of obesity.肥胖的临床及经济后果。
Am J Manag Care. 2013;19(10 Suppl):s219-28.
10
Financial impact of obesity and bariatric surgery.肥胖症及减重手术的经济影响
Med Clin North Am. 2007 May;91(3):321-38, ix. doi: 10.1016/j.mcna.2007.01.001.

引用本文的文献

1
Effective management of obesity.肥胖的有效管理。
Qual Health Care. 1997 Sep;6(3):170-5. doi: 10.1136/qshc.6.3.170.
2
Sibutramine. A review of its contribution to the management of obesity.西布曲明。对其在肥胖症管理中作用的综述。
Drugs. 1998 Dec;56(6):1093-124. doi: 10.2165/00003495-199856060-00019.
3
Dexfenfluramine. An updated review of its therapeutic use in the management of obesity.右芬氟拉明。关于其在肥胖症治疗中应用的最新综述。

本文引用的文献

1
The indirect costs of obesity to society.肥胖给社会带来的间接成本。
Pharmacoeconomics. 1994;5(Suppl 1):58-61. doi: 10.2165/00019053-199400051-00012.
2
Socioeconomic consequences of obesity: the effect of obesity on the individual.
Pharmacoeconomics. 1994;5(Suppl 1):54-7. doi: 10.2165/00019053-199400051-00011.
3
The cost of obesity: the Australian perspective.肥胖的代价:澳大利亚视角
Pharmacoeconomics. 1994;5(Suppl 1):45-52. doi: 10.2165/00019053-199400051-00009.
Drugs. 1996 Nov;52(5):696-724. doi: 10.2165/00003495-199652050-00007.
4
Obesity in Europe: prevalence and consequences for use of medical care.欧洲的肥胖问题:患病率及对医疗保健使用的影响。
Pharmacoeconomics. 1994;5(Suppl 1):38-44. doi: 10.2165/00019053-199400051-00008.
5
The cost of obesity: the US perspective.肥胖的代价:美国视角
Pharmacoeconomics. 1994;5(Suppl 1):34-7. doi: 10.2165/00019053-199400051-00007.
6
Options for the management of obesity.
Pharmacoeconomics. 1994;5(Suppl 1):18-32. doi: 10.2165/00019053-199400051-00005.
7
Causes, diagnosis and risks of obesity.
Pharmacoeconomics. 1994;5(Suppl 1):8-17. doi: 10.2165/00019053-199400051-00004.
8
Health-related quality of life assessment and the pharmaceutical industry.健康相关生活质量评估与制药行业。
Pharmacoeconomics. 1992 Jun;1(6):394-408. doi: 10.2165/00019053-199201060-00002.
9
Cost-of-illness studies: a major headache?疾病成本研究:一大难题?
Pharmacoeconomics. 1992 Jul;2(1):1-4. doi: 10.2165/00019053-199202010-00001.
10
Morbid obesity and related health risks.病态肥胖及相关健康风险。
Ann Intern Med. 1985 Dec;103(6 ( Pt 2)):1043-7. doi: 10.7326/0003-4819-103-6-1043.